Shannon R. Mccurdy

Hematology

3400 Civic Center Boulevard
West Pavilion, 4th Floor
Philadelphia, PA 19104

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 88 publications

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 13, 2026

Editorial: NK cells in transplantation.

Editorial: NK cells in transplantation.

Journal: Frontiers in immunology

Published: May 15, 2026

Longitudinal short-term assessments of single- and multi-protein disease activity biomarkers to determine reliability and the minimum detectable change in people with clinically stable RRMS.

Longitudinal short-term assessments of single- and multi-protein disease activity biomarkers to determine reliability and the minimum detectable change in people with clinically stable RRMS.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: May 06, 2026

Hematopoietic Cell Transplant Access and Patient Diversity.

Hematopoietic Cell Transplant Access and Patient Diversity.

Journal: JAMA network open

Published: May 05, 2026

Absolute risk trade-offs of donor age, sex, and graft source in PTCy-based transplantation.

Absolute risk trade-offs of donor age, sex, and graft source in PTCy-based transplantation.

Journal: Blood advances

Published: March 09, 2026

Absolute Risk Trade-offs of Donor Age, Sex, and Graft Source in PTCy-Based Transplantation.

Absolute Risk Trade-offs of Donor Age, Sex, and Graft Source in PTCy-Based Transplantation.

Journal: Blood advances

Published: March 09, 2026

Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age.

Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age.

Journal: Leukemia

Published: November 12, 2025

Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional Prophylaxis.

Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional Prophylaxis.

Journal: JAMA oncology

Published: November 06, 2025

Challenging a clinical dogma with multimodal machine learning: a retrospective analysis of transplant mismatched donor selection.

Challenging a clinical dogma with multimodal machine learning: a retrospective analysis of transplant mismatched donor selection.

Journal: Leukemia

Published: October 28, 2025

CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study.

CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study.

Journal: Blood advances

Published: September 08, 2025

CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.

CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.

Journal: Blood advances

Published: September 08, 2025

Allogeneic Transplantation for Older Adults.

Allogeneic Transplantation for Older Adults.

Journal: Advances in experimental medicine and biology

Published: June 09, 2025

Showing 1-12 of 88

Last Updated: 09/26/2026